Nikita Kotlov
0000-0002-6393-7357
BostonGene LLC
82 papers found
Refreshing results…
Data from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Supplementary Figures from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Supplementary Figure S1 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Supplementary Figure from Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Data from Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Supplementary Figure S3 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Supplementary Table S2 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Supplementary Table S1 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Supplementary Date from Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Supplementary Figure S2 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Supplementary Figure S4 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Supplementary Data from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Data from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Abstract P5-02-45: An HRD scoring system based on long-focal copy number alterations predictive of PARP inhibitor response
Abstract P4-09-02: A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival
Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma
B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
Combinatory Technology for Single Sample Gene Expression Projection onto a Cohort Sequenced with a Different Technology
Tumor immunity portrait: An AI-driven molecular predictor combining tumor microenvironment and tumor mutational burden for immune checkpoint inhibitor response prediction
Genomic characterization of the GATA3 mutational landscape in breast cancer
Missing publications? Search for publications with a matching author name.